當前位置：   首頁 > 需求大廳

 >  生產研發 

需求內容：由透明質酸均屬于多糖類物質，應用該原料交聯合成的水凝膠可避免異基因蛋白組分的凝膠帶來的免疫學疑慮，部分廠家透明質酸凝膠產品吸水性強，與皮膚組織相容性好，可塑性強，可以根據不同需要塑性。 技術指標： 1. 體內停留時間可達到6個月以上 2. 有較好的細胞相容性、組織相容性 3. 可用于顏面部注射 4. 顆粒度均一，并可根據需要調節生產不同顆粒度的凝膠 5. 生產成本在200元/毫升以下 6. 1年內可獲SFDA批準用于臨床試驗（含已獲SFDA批準）   [更多]

罕見癌癥研究基金會(RCRF),致力于通過戰略投資和創新合作進行基礎治療罕見的癌癥,和美國文化募捐組織(ATCC),世界上最大的非營利性細胞株庫,建立神經內分泌腫瘤細胞株收集目錄。腸道良性腫瘤和胰腺神經內分泌腫瘤(PNET)需求一種新療法的研究和發展，即在體內原發性腫瘤中建立新的細胞株。 為了刺激發展新的良性腫瘤和PNET細胞系,該基金會是高興地宣布第二次開放競爭十個人獎項:開發人員的第一個新的細胞系在每個疾病(腸道良性腫瘤和PNET)將獲得100000美元，開發者的第二,第三,第四,第五個新細胞系在每個疾病將會收到50000美元。原文如下：https://www.innocentive.com/ar/challenge/9933756 The lack of well-validated and widely accepted cell lines derived from intestinal carcinoid and pancreatic neuroendocrine tumors (PNET) is a significant barrier for research and development of new therapies. The Caring for Carcinoid Foundation therefore wishes to launch a second Challenge to stimulate a concerted effort to create a “collection” of well-characterized cell lines that faithfully replicate tumor characteristics and genetics. The Foundation has partnered with the Rare Cancer Research Foundation (RCRF), a foundation dedicated to curing rare cancers through strategic investments and innovative collaborations, and the American Type Culture Collection (ATCC), the world’s largest non-profit cell line repository, to establish a Neuroendocrine Tumor Cell Line collection in their catalog. This is a Reduction-to-Practice Challenge that requires written documentation, detailed description of each cell line, and sample delivery. Source: InnoCentive Challenge ID: 9933756 Challenge Overview This Challenge is intended to encourage innovative approaches to establishing new cell lines from primary tumors that grow slowly in vivo and to publicize new methods as well as availability of the new cell lines for broad, unrestricted use. To stimulate development of new carcinoid and PNET cell lines, the Foundation is pleased to announce its second open competition for up to ten individual prizes: Developers of the first new cell lines in each disease (intestinal carcinoid and PNET) will receive $100,000 each and developers of the second, third, fourth, and fifth new cell lines in each disease will receive $50,000 each. Individual   [更多]

兩個藥品試行標準轉正，要求100%通過，尋求代理，非誠勿擾。   [更多]

本公司因項目需要，對外委托基因毒性雜質研究：肼基、疊氮、氯代烷烴、酰氯類、氰化物等；請有研究能力的公司與我們聯系。 項目要求： 1、完成以上基因毒性雜質的方法學開發、驗證資料； 2、研究機構具有與實驗相匹配的設備，并經過驗證； 3、受委托機構可以接受審計及研制現場核查； 4、研究資料符合數據完整性要求；   [更多]

品種1：抗腫瘤類，50ml西林瓶 品種2：抗生素類，5ml西林瓶 品種3：抗生素類，10ml西林瓶 以上3個品種均為凍干粉針，我公司需要尋找凍干車間，制備3批中試樣品（3批注冊批），主要服務是提供中試生產場地及協助我們進行中試3批生產。希望能提供服務的公司與我聯系，服務價格我預估在10萬左右（每個品種10萬，只是我個人預估的），實際成交價格可以面談。   [更多]

排行世界的第五大的制藥公司尋找合作伙伴，要求提供多種大環結構藥物與合成技術，尋找有關大環領域的新藥發現。希望此公司提供化學詳細的3 d模型。具體請鏈接：https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.   [更多]

彌漫性大B細胞淋巴瘤(DLBCL)是一種最常見的非霍奇金淋巴瘤，診斷病例在美國約占淋巴瘤的30%。它是一種特異質性疾病。由于臨床多樣性和復雜性,又有新的突變在某些難治性患者身上被發現。阿斯利康需要創建一種彌漫性巨大B細胞淋巴瘤的合適的臨床模型。 具體鏈接在：https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.   [更多]

順苯磺阿曲庫銨為經典的中時效的非去極化肌松藥，在臨床麻醉中應用普遍。分子中含有4個手性中心，其中2個為手性碳，2個為手性氮，順苯磺阿曲庫銨為1R,1'R,2R,2'R異構體。我方需求順苯磺阿曲庫銨大生產合成工藝，要求整個工藝有較好的選擇性，反應的收率和產品的純度較高，盡量降低成本。   [更多]

甲基多巴  METHYL DOPA  CAS 555-30-6求購：原料藥 甲基多巴的商業化生產工藝，非專利網的文獻。有實際完整生產工藝的可以詳談！甲基多巴是一種抗高血壓藥，為白色或類白色結晶性粉末；無臭。其主要是在中樞轉化成甲基去甲腎上腺素。甲基去甲腎上腺素是一種很強的中樞α2受體激動藥。用于中、重度或惡性高血壓，還有鎮靜、降低眼壓作用。   [更多]

求購 苯磺順阿曲庫銨 原料藥 商業化生產工藝！Q2736068151苯磺順阿曲庫銨(cisatracurium besylate)是最新一代肌松劑，廣泛應用于氣管 插管、肝腎功能障礙、心血管手術等領域。苯磺酸阿曲庫銨有4個手性中心，10個同分異構體，分子中含有4個手性中心，其中2個為手性碳，2個為手性氮，順苯磺阿曲庫銨為1R,1'R,2R,2'R異構體。我方需求順苯磺阿曲庫銨大生產合成工藝，要求整個工藝有較好的選擇性，反應的收率和產品的純度較高。我司需要商業化生產工藝而不是 專利網文獻，需求真實有效，可提供者可私聊！   [更多]